CureDM and Sanofi-Aventis sign agreement over Pancreate

CureDM LLC, has signed an agreement with Sanofi-Aventis for the exclusive worldwide license of Pancreate (proisletide acetate).

The first-in-class human peptide therapeutic is a novel islet neogenesis agent indicated for the treatment of type one and type two diabetes.

Scientists from privately held biopharmaceutical company CureDM discovered Pancreate and the firm holds several key patents for the treatment.

Under the new agreement, Sanofi-Aventis holds the exclusive worldwide rights to manufacture, develop and market Pancreate for the treatment of diabetes in human and animal patients.

Dr Joseph Reiser, president and chief executive officer of CureDM, said the company was “extremely pleased” about the agreement with Sanofi-Aventis.

“We believe that Sanofi-Aventis is the ideal partner to bring our novel therapeutic approach to patients, given Sanofi’s leading and far-reaching strategic commitment in the field of diabetes,” he added.

Last month, a new blood glucose meter called Contour USB was launched by Bayer Diabetes Care in Ireland and the UK.